Term
|
Definition
|
|
Term
|
Definition
| Prompt, effective bronchodilation |
|
|
Term
| Albuterol - clinical applications? |
|
Definition
| asthma, COPD, DOC for acute asthmatic bronchospasm |
|
|
Term
| Albuterol - Kinetics, tox? |
|
Definition
| aerosol inhalation, several hour DOA, available for neb and parenteral, tremor, tachy, OD- arrthymias |
|
|
Term
|
Definition
|
|
Term
|
Definition
| slow onset, primarily preventive, potentiates corticosteriod effects |
|
|
Term
| Salmeterol - clinical applications? |
|
Definition
|
|
Term
| Salmeterol - kinetics, tox? |
|
Definition
| aerosol inhalation, 12-24 DOA, tox - tremor, tachy, OD - arrythmias |
|
|
Term
| How do metaproterenol and terbutaline differ from the class prototype? |
|
Definition
| Similar to albuterol, terbutaline is available as an oral drug |
|
|
Term
| Formoterol is similar to... |
|
Definition
|
|
Term
|
Definition
| nonselective a and B agonist |
|
|
Term
|
Definition
| bronchodilation plus all other sympathomimetic effects on CV and other organ systems |
|
|
Term
| Epinephrine - clinical applications? |
|
Definition
| anaphylaxis, asthma, others, rarely used for asthma because B2 selective agonists are preferred |
|
|
Term
| Epinephrine - kinetics, tox? |
|
Definition
| aerosol, neb or parenteral |
|
|
Term
|
Definition
|
|
Term
|
Definition
| bronchodilation plus powerful CV effects |
|
|
Term
| Isoproterenol - clinical applications? |
|
Definition
| asthma, but B2 selective agents are preferred |
|
|
Term
| Isoproterenol - kinetics, tox? |
|
Definition
| aerosol, neb or parenteral |
|
|
Term
| Fluticasone, inhaled - MOA? |
|
Definition
|
|
Term
| Fluticasone, inhaled - effects? |
|
Definition
| reduces mediators of inflammation, powerful prophylaxis of exacerbations |
|
|
Term
| Fluticasone, inhaled - clinical applications? |
|
Definition
|
|
Term
| Fluticasone, inhaled - kinetics, neb? |
|
Definition
| aerosol, duration hours, tox - limited by aerosol application, candidal infection, vocal cord changes |
|
|
Term
| Beclomethasone, budesonide, flunisolide, others - similar to... |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| reduces mediators of inflammation, powerful prophylaxis of exacerbations |
|
|
Term
| Prednisone - clinical applications? |
|
Definition
|
|
Term
| Prednisone - kinetics, tox? |
|
Definition
| Oral, 12-24 hr DOA, tox - multiple (related to adrenal suppression) |
|
|
Term
| Methylprednisolone is similar to what other drug? How is it administered? |
|
Definition
|
|
Term
| Cromolyn and nedocromil - MOA? |
|
Definition
| alters function of delayed chloride channels, inhibits inflammatory cell activation |
|
|
Term
| Cromolyn and nedocromil - clinical effects? |
|
Definition
| prevents acute bronchospasm |
|
|
Term
| Cromolyn and nedocromil - clinical applications? |
|
Definition
| asthma, other routes used for ocular, nasal and GI allergy |
|
|
Term
| Cromolyn and nedocromil - kinetics, tox? |
|
Definition
| aerosol, 6-8 hr DOA, tox - cough, not absorbed so other tox is minimal |
|
|
Term
|
Definition
| uncertain, PDE inhibition, adenosine receptor antagonist |
|
|
Term
|
Definition
| bronchodilation, cardiac stimulation, increased skeletal muscle strength |
|
|
Term
| Theophylline - clinical applications? |
|
Definition
|
|
Term
| Theophylline - kinetics, tox? |
|
Definition
| oral, 8-12 hr DOA but extended release preps often used, tox - multiple (think caffeine) |
|
|
Term
| Montelukast, zafirlukast - MOA? |
|
Definition
| block leukotriene D4 receptors |
|
|
Term
| Montelukast, zafirlukast - effects? |
|
Definition
| block airway response to exercise and antigen challenge |
|
|
Term
| Montelukast, zafirlukast - clinical applications? |
|
Definition
| prophylaxis of asthma, especially in children and in aspirin-induced asthma |
|
|
Term
| Montelukast, zafirlukast - kinetics, tox? |
|
Definition
| oral, duration hours, tox is minimal |
|
|
Term
|
Definition
| humanized IgE antibody reduces circulating IgE |
|
|
Term
|
Definition
| reduces frequency of asthma exacerbations |
|
|
Term
| Omalizumab - clinical applications? |
|
Definition
| severe asthma inadequately controlled by other agents |
|
|
Term
| Omalizumab - kinetics, tox? |
|
Definition
| parenteral, 2-4d duration, tox - injection site reactions, anaphylaxis extremely rare |
|
|
Term
|
Definition
| inhibits lipoxygenase, reduces synthesis of leukotrienes |
|
|
Term
| What is a muscarinic antagonist used in asthma? |
|
Definition
|
|
Term
|
Definition
| a longer acting, somewhat selective antimuscarinic agent, approved for COPD, alternative to longer acting B agonists for asthma but still under investigation |
|
|
